Face2Face Africa on MSN
‘This is rare!’ Elite athlete and breast cancer survivor shares story after shock diagnosis at 26
In October 2022, she discovered a small lump and sought medical attention. Despite her concerns, she was reassured that ...
Tammy McDevitt didn't know what lobular cancer was until she got her diagnosis; now with treatment behind her, she shares ...
One in eight women will develop breast cancer in their lifetime, a stark reality that underscores the critical importance of ...
October is Breast Cancer Awareness Month. According to the National Breast Cancer Foundation, breast cancer death rates in ...
Tucatinib enhances progression-free survival (PFS) in HER2+ metastatic breast cancer, showcasing promising results in a ...
Lobular breast cancer accounts for more than 10% of all breast cancer cases in the U.S., and incidence rates have increased ...
Myeloid Therapeutics has rebranded as Create Medicines and unveiled a drug development strategy adding to its initial emphasis on cancer treatments.
The trial, performed at Radboud University Medical Center, will test TGW211, which involves a trigger designed to limit off-target effects of the radioactive material.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback